Skip to main content

Metabolomics Firm Metabolon Raises $13.1M

NEW YORK (GenomeWeb News) – Metabolomics firm Metabolon today announced it has completed a Series D financing round that raised $13.1 million.

New investor Keating Capital participated in the round, which also included existing investors Sevin Rosen Funds, Aurora Funds, Harris & Harris Group; Syngenta Ventures, Fletcher Spaght, and Fulcrum Financial Partners.

The Research Triangle Park, NC-based firm raised $12.3 million in a Series C round two years ago.

John Ryals, president and CEO of Metabolon, said in a statement that the funds will be used to support growth of its Metabolytics division, which provides biochemical profiling services, as well as ongoing development of Metabolon's diagnostics products portfolio.

The company, which had been primarily a service business, moved into the diagnostics space earlier this year. Its first diagnostic test, called Quantose, targets insulin-resistance and is in final CLIA validation, Todd Lynch, Metabolon's CFO said in an e-mail to GenomeWeb Daily News. He added that the test is anticipated to launch by the end of the year.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.